Jiangsu Lianhuan Pharmaceutical (600513.SH): The application for listing the chemical raw material drug Agamaban has been approved.

Lu'anhuan Pharmaceuticals (600513.SH) announced that the company recently received the "Chemical raw material drug marketing application approval notice" from the National Medical Products Administration for the active pharmaceutical ingredient Argatroban. Argatroban is a direct thrombin inhibitor that reversibly binds to the active site of thrombin. Its injection is suitable for improving the neurological symptoms (motor paralysis) and daily activities (walking, standing, sitting, eating) of patients in the acute phase of ischemic stroke within 48 hours of onset; as well as improving the ulceration, rest pain, and cold sensation in the limbs of patients with chronic arterial occlusive disease (thromboangiitis obliterans, occlusive arteriosclerosis).